Automatic auditory processing features in distinct subtypes of patients at clinical high risk for psychosis: Forecasting remission with mismatch negativity

Wu, GuiSen; Tang, Xiaochen; Gan, RanPiao; Zeng, Jiahui; Hu, YeGang; Xu, Li-Hua; Wei, Yanyan; Tang, Yingying; Chen, Tao; Liu, HaiChun; Li, Chunbo; Wang, Jijun; Zhang, Tianhong

doi:10.1002/hbm.26021

Cited by 4 publications

(2 citation statements)

References 55 publications

(72 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Measures of MMN are correlated to the magnitude of these sensory processing deficits ( 38 ). Consistent with that, recent studies revealed that reduced MMN is particularly present in a subgroup of patients with marked cognitive deficits and poor social functioning ( 34 , 39 , 40 ) and predicts poor response to therapy with common antipsychotics ( 41 , 42 ). Studies on the neurophysiological substrate of MMN reductions have demonstrated associations to hypofunction of the glutamatergic NMDA receptor ( 43 ).…”

Section: Possible Biomarkers For Muscarinic Dysfunction In Schizophreniasupporting

confidence: 63%

Markers of muscarinic deficit for individualized treatment in schizophrenia

Stuke

2023

Front. Psychiatry

View full text Add to dashboard Cite

Recent clinical studies have shown that agonists at muscarinic acetylcholine receptors effectively reduce schizophrenia symptoms. It is thus conceivable that, for the first time, a second substance class of procholinergic antipsychotics could become established alongside the usual antidopaminergic antipsychotics. In addition, various basic science studies suggest that there may be a subgroup of schizophrenia in which hypofunction of muscarinic acetylcholine receptors is of etiological importance. This could represent a major opportunity for individualized treatment of schizophrenia if markers can be identified that predict response to procholinergic vs. antidopaminergic interventions. In this perspective, non-response to antidopaminergic antipsychotics, specific symptom patterns like visual hallucinations and strong disorganization, the presence of antimuscarinic antibodies, ERP markers such as mismatch negativity, and radiotracers are presented as possible in vivo markers of muscarinic deficit and thus potentially of response to procholinergic therapeutics. Finally, open questions and further research steps are outlined.

show abstract

Section: Possible Biomarkers For Muscarinic Dysfunction In Schizophreniasupporting

confidence: 63%

Markers of muscarinic deficit for individualized treatment in schizophrenia

Stuke

2023

Front. Psychiatry

View full text Add to dashboard Cite

show abstract

“…ERP components under different paradigms can effectively reflect the abnormal mechanisms of brain function in patients with psychosis. The SHARP team 26 systematically studied the characteristics of mismatch negativity (MMN) in the CHR population. The MMN is a widely studied ERP component that reflects the processing of preattention auditory information.…”

Section: Shanghai At Risk For Psychosis (Sharp)mentioning

confidence: 99%

Comprehensive review of multidimensional biomarkers in the ShangHai At Risk for Psychosis (SHARP) program for early psychosis identification

Zhang,

Xu,

Tang

et al. 2023

PCN Reports

Self Cite

View full text Add to dashboard Cite

Psychosis is recognized as one of the largest contributors to nonfatal health loss, and early identification can largely improve routine clinical activity by predicting the psychotic course and guiding treatment. Clinicians have used the clinical high‐risk for psychosis (CHR) paradigm to better understand the risk factors that contribute to the onset of psychotic disorders. Clinical factors have been widely applied to calculate the individualized risks for conversion to psychosis 1–2 years later. However, there is still a dearth of valid biomarkers to predict psychosis. Biomarkers, in the context of this paper, refer to measurable biological indicators that can provide valuable information about the early identification of individuals at risk for psychosis. The aim of this paper is to critically review studies assessing CHR and suggest possible biomarkers for application of prediction. We summarized the studies on biomarkers derived from the findings of the ShangHai at Risk for Psychosis (SHARP) program, including those that are considered to have the most potential. This comprehensive review was conducted based on expert opinions within the SHARP research team, and the selection of studies and results presented in this paper reflects the collective expertise of the team in the field of early psychosis identification. The three dimensions with potential candidates include neuroimaging dimension of brain structure and function, electrophysiological dimension of event‐related potentials (ERPs), and immune dimension of inflammatory cytokines and complement proteins, which proved to be useful in supporting the prediction of psychosis from the CHR state. We suggest that these three dimensions could be useful as risk biomarkers for treatment optimization. In the future, when available for the integration of multiple dimensions, clinicians may be able to obtain a comprehensive report with detailed information of psychosis risk and specific indications about preferred prevention.

show abstract

Automatic auditory processing features in distinct subtypes of patients at clinical high risk for psychosis: Forecasting remission with mismatch negativity

Tang

Gan

et al. 2022

Human Brain Mapping

Self Cite

View full text Add to dashboard Cite

Individuals at clinical high risk (CHR) for psychosis exhibit a compromised mismatch negativity (MMN) response, which indicates dysfunction of pre-attentive deviance processing. Event-related potential and time-frequency (TF) information, in combination with clinical and cognitive profiles, may provide insight into the pathophysiology and psychopathology of the CHR stage and predict the prognosis of CHR individuals.A total of 92 individuals with CHR were recruited and followed up regularly for up to 3 years. Individuals with CHR were classified into three clinical subtypes demonstrated previously, specifically 28 from Cluster 1 (characterized by extensive negative symptoms and cognitive deficits), 31 from Cluster 2 (characterized by thought and behavioral disorganization, with moderate cognitive impairment), and 33 from Cluster 3 (characterized by the mildest symptoms and cognitive deficits). Auditory MMN to frequency and duration deviants was assessed. The event-related spectral perturba-

show abstract

Automatic auditory processing features in distinct subtypes of patients at clinical high risk for psychosis: Forecasting remission with mismatch negativity

Cited by 4 publications

References 55 publications

Markers of muscarinic deficit for individualized treatment in schizophrenia

Markers of muscarinic deficit for individualized treatment in schizophrenia

Comprehensive review of multidimensional biomarkers in the ShangHai At Risk for Psychosis (SHARP) program for early psychosis identification

Automatic auditory processing features in distinct subtypes of patients at clinical high risk for psychosis: Forecasting remission with mismatch negativity

Contact Info

Product

Resources

About